Objectives: The therapeutics for inhibition of bone loss for postmenopausal women need to be developed, considering the fact that there are only three bone-anabolic treatments for osteoporosis approved by the FDA. The present study aimed to find the osteogenic drugs derived from functional food materials, upon integrating network analysis and pre-clinical studies into clinical trials. Methods: Osteo-F, a new herbal formulation for improving bone loss, consisting of the fruits of Schizandra chinensis (Turcz.) Baill. and Lycium chinense Mill., and the root of Eucommia ulmoides Oliv. The potential target pathway of Osteo-F was predicted from network pharmacology analysis. Based on the network analysis, bone-forming markers including collagen, BMP-2 and osteocalcin as well as the femoral BMD were investigated in vitro and in vivo. Subsequently, a randomized, double-blind, placebo-controlled clinical trial for 24 weeks with Osteo-F supplementation was conducted in postmenopausal women. Results: The network pharmacology analysis showed that a potential mechanism of Osteo-F is closely related to osteoblast differentiation. Consistent with the predicted mechanism, Osteo-F treatment significantly enhanced bone matrix formation and mineralization with collagen expression in osteoblasts. Simultaneously, secreted bone-forming molecules were upregulated by Osteo-F. After the administration of Osteo-F to osteoporotic mice, the femoral BMD and osteocalcin in the serum and bone tissues were significantly improved. A randomized, double-blinded, placebo-controlled clinical trial showed that 253 mg of Osteo-F supplementation for 24 weeks result-ed in significant improvements in the Z-score and serum osteocalcin levels of postmenopausal women compared to the placebo, thus indicating bone anabolic efficacy. Conclusion: In the current study, the bone anabolic effect of Osteo-F was determined by activating the differentiation and mineralization of osteoblasts through integrating experiments based on network analysis into clinical trials, with synchronized, reliable evidence, demonstrating that Osteo-F is a novel bone anabolic treatment in postmenopausal women.